Effects of curcuminoids on inflammatory and oxidative stress biomarkers and clinical outcomes in critically ill patients: A randomized <scp>double‐blind placebo‐controlled</scp> trial

Zahedi, Hoda; Hosseinzadeh‐Attar, Mohammad Javad; Shadnoush, Mahdi; Sahebkar, Amirhossein; Barkhidarian, Bahareh; Sadeghi, Omid; Najafi, Atabak; Hosseini, Saeed; Qorbani, Mostafa; Ahmadi, Arezoo; Ardehali, Seyed Hossein; Norouzy, Abdolreza

doi:10.1002/ptr.7179

Cited by 23 publications

(23 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, curcumin is a safe phytochemical and well‐tolerated. This food supplement has been used in different diseases even in critical health conditions such as cancer patients and trauma and sepsis patients in the intensive care unit without any considerable adverse effects (Aggarwal, Kumar, & Bharti, 2003; Dhillon et al, 2008; Hsieh, 2001; Karimi et al, 2020; Zahedi et al, 2021). It is shown that supplementation with 8,000 mg curcumin/day for 3 months resulted in no toxicity, only some gastrointestinal discomfort, namely, nausea and diarrhea (Chainani‐Wu, 2003; Hsu & Cheng, 2007).…”

Section: Discussionmentioning

confidence: 99%

The clinical use of curcumin on neurological disorders: An updated systematic review of clinical trials

Mohseni

Sahebkar

Askari

et al. 2021

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Neuroprotective effects of curcumin have been shown in previous studies. This updated systematic review of clinical trials aimed to investigate the effect of curcumin on neurological disorders. Databases including PubMed, Scopus, Web of Science, and Google Scholar were systematically searched to identify clinical trials investigating the effects of curcumin/turmeric supplements alone, or in combination with other ingredients, on neurological diseases. Nineteen studies comprising 1,130 patients met the inclusion criteria. Generally, intervention and study outcomes were heterogeneous. In most of the studies, curcumin had a favorable effect on oxidative stress and inflammation. However, with the exception of AD, curcumin supplementation either alone, or in combination with other ingredients, had beneficial effects on clinical outcomes for the other aforementioned neurodegenerative diseases. For example, the frequency, severity, and duration of migraine attacks, scores on the revised ALS functional rating scale, and the occurrence of motor complications in PD were all significantly improved with curcumin supplementation either alone or in combination with other ingredients. However, in three studies, several adverse side effects (mostly gastrointestinal in nature) were reported. Curcumin supplementation may have favorable effects on inflammatory status and clinical outcomes of patients with neurological disease, although the results were not consistent.

show abstract

Section: Discussionmentioning

confidence: 99%

The clinical use of curcumin on neurological disorders: An updated systematic review of clinical trials

Mohseni

Sahebkar

Askari

et al. 2021

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…The required sample size in each group has been equal to 24 people, and with considering the drop out patients, the sample size will be practically 30 patients in every group, which we will consider a total of 60. It seems that this sample size is small; however, several articles which conducted among ICU patients used a small sample size based on a formula like our ones and worked on about 60 patients [ 26 – 28 ].…”

Section: Methods: Participants Interventions and Outcomesmentioning

confidence: 99%

The effects of l-carnitine supplementation on inflammatory factors, oxidative stress, and clinical outcomes in patients with sepsis admitted to the intensive care unit (ICU): study protocol for a double blind, randomized, placebo-controlled clinical trial

Keshani

Alikiaii

Askari

et al. 2022

Trials

View full text Add to dashboard Cite

Background Sepsis is a common cause for admission to the intensive care unit (ICU), and its incidence has been increasing. It is associated with a significant increase in serum inflammatory biomarkers such as C-reactive protein (CRP) and cytokines such as interleukin 1 (IL-1), IL-6, and tumor necrosis factor (TNF). Sepsis is also associated with pathophysiological changes that include fluid accumulation in the lungs, eventually leading to acute respiratory distress syndrome (ARDS), tissue edema, hypotension, and acute kidney injury (AKI). Conventional therapies include antibiotics, but these may have important adverse effects, so novel therapeutic approaches are required. In animal studies, l-carnitine improves antioxidant status, and in some clinical trials, it has been shown to reduce inflammation. It has also been shown to improve respiratory distress and help maintain coenzyme A homeostasis, metabolic flexibility, promoting the normal function of the tricarboxylic acid (TCA) cycle, and oxidation of fatty acids by peroxisomes. We aim to determine the effects of very high doses of l-carnitine on inflammatory factors, oxidative stress, and clinical outcomes of patients with sepsis in ICU. Method and design In this double-blind, randomized controlled clinical trial, we will use block randomization of 60 patients with sepsis, aged between 20 and 65 years from Al-Zahra Hospital, Isfahan, Iran. The intervention group (n = 30) will receive three capsules of l-carnitine (each capsule contains 1000 mg l-carnitine; totally 3000 mg/day) for 7 days, and a control group (n = 30) will receive a placebo with the same dose and for the same duration in addition to usual care. At baseline, scores for clinical and nutritional status (Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), Quick SOFA (qSOFA), and NUTRIC Score) will be assessed. At beginning and end point of the study, inflammatory markers (CRP, erythrocyte sedimentation rate (ESR)), oxidative stress status (total oxidative stress (TOS), total antioxidant capacity (TAC)), and clinical variables will be evaluated also. The mortality rate will be assessed within 28 days of the beginning of the intervention. Discussion Because of the anti-inflammatory and antioxidant properties of l-carnitine, it is possible that using a high dose of 3000 mg daily of this nutritional supplement may reduce inflammation and oxidative stress and improve subsequent mortality of critically ill patients with sepsis. Trial registration Iranian Registry of Clinical Trials IRCT20201129049534N1. Registered on 2 May 2021.

show abstract

“…Of the studies investigating TBI-related curcumin between 2005 and 2022, 42 were clinical trials. 30,31 The number of studies investigating curcumin in TBI through drug delivery system is three [32][33][34] (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…There was a significant decrease in serum leptin levels in the curcuminoids group compared to the placebo group; however, despite supplementation with curcuminoids, serum concentrations of adiponectin in cases with TBI did not change. 30 Zahedi et al 31 reported that the effects of curcuminoid supplementation on inflammatory and oxidative stress biomarkers, clinical outcomes, and nutritional status in critically ill patients with TBI are unknown, although the beneficial effects of polyphenolic curcuminoids in the treatment of TBI have been proposed in experimental studies. In one such study, serum levels of interleukin-6, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and C-reactive protein were significantly decreased in patients treated with curcuminoid compared to the placebo group.…”

Section: Discussionmentioning

confidence: 99%

Curcumin-Impregnated Drug Delivery Systems May Show Promise in the Treatment of Diseases Secondary to Traumatic Brain Injury: Systematic Review

Yılmaz

Karaarslan

Somay

et al. 2022

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Background Traumatic brain injury (TBI) is a major social health problem, especially in young adults, and progresses with advanced functional losses. In this study, curcumin was directed to the damaged brain tissue by crossing the blood–brain barrier through drug delivery systems. Thus, the study asked whether it can be effective in the treatment of TBI, which has not had a radical treatment method in clinics yet. Methods A comprehensive and systematic literature search in the PubMed electronic database was performed. Descriptive statistics were used to evaluate the data obtained. The results were presented as frequency and percentage (%) or amount. Results Two clinical trials investigated curcumin for the treatment of TBI. One study tested curcumin in living mammalian subjects using an amyloLipid nanovesicle. In three studies, curcumin was investigated together with the drug delivery system for the treatment of TBI. Conclusion Drug delivery systems prepared with nanomaterials may have a potential therapeutic effect in treating TBI by increasing neuroprotection because they can penetrate the central nervous system more rapidly.

show abstract

Effects of curcuminoids on inflammatory and oxidative stress biomarkers and clinical outcomes in critically ill patients: A randomized double‐blind placebo‐controlled trial

Cited by 23 publications

References 48 publications

The clinical use of curcumin on neurological disorders: An updated systematic review of clinical trials

The clinical use of curcumin on neurological disorders: An updated systematic review of clinical trials

The effects of l-carnitine supplementation on inflammatory factors, oxidative stress, and clinical outcomes in patients with sepsis admitted to the intensive care unit (ICU): study protocol for a double blind, randomized, placebo-controlled clinical trial

Curcumin-Impregnated Drug Delivery Systems May Show Promise in the Treatment of Diseases Secondary to Traumatic Brain Injury: Systematic Review

Contact Info

Product

Resources

About